jacmar, out of the entire call, my mind focused in on Gerald's comments about Eli Lilly's purchase of Avid Radiopharmaceuticals in order to acquire the Amyvid test. Gerald described this valuation of Amyvid at length and made comparison to how Amarantus was proceeding with LymPro.

By not partnering with BP now and and continuing testing through our CLIA lab partner to improve the asset value even further, I'm beginning to think Gerald is preparing the company for a massive sale of LymPro down the road, probably around the time of FDA approval. Until that time, our company can reap a high percentage of the revenues generated by LymPro ourselves. Our holding company structure, plus Gerald's discussions of possible spinoff options for various divisions or asset classes would support this path.

Did anyone else pick up on this?